Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Akero Therapeutics Analyst Ratings and Price Targets | NASDAQ:AKRO | Benzinga
Akero Therapeutics Inc has a consensus price target of $68.33 based on the ratings of 11 analysts. The high is $109 issued by UBS on January 31, 2025. The low is $38 issued by Evercore ISI Group on May 15, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., UBS, and B of A Securities on March 3, 2025, January 31, 2025, and January 30, 2025, respectively. With an average price target of $82.33 between HC Wainwright & Co., UBS, and B of A Securities, there's an implied 83.00% upside for Akero Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
UBS
B of A Securities
Morgan Stanley
Citigroup
1calculated from analyst ratings
Analyst Ratings for Akero Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/03/2025 | Buy Now | 66.7% | HC Wainwright & Co. | Ed Arce62% | $72 → $75 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | 142.28% | UBS | Eliana Merle46% | $42 → $109 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | 40.03% | B of A Securities | Alexandria Hammond43% | $35 → $63 | Upgrade | Neutral → Buy | Get Alert |
| 01/28/2025 | Buy Now | 113.38% | Morgan Stanley | Michael Ulz57% | $46 → $96 | Maintains | Overweight | Get Alert |
| 01/28/2025 | Buy Now | 77.82% | Citigroup | Jonathan Woo50% | $65 → $80 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | 62.26% | Canaccord Genuity | Edward Nash66% | $56 → $73 | Maintains | Buy | Get Alert |
| 01/27/2025 | Buy Now | 60.04% | HC Wainwright & Co. | Ed Arce62% | $50 → $72 | Maintains | Buy | Get Alert |
| 01/16/2025 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 44.48% | Citigroup | Jonathan Woo50% | → $65 | Initiates | → Buy | Get Alert |
| 11/18/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal38% | — | Reiterates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal38% | — | Reiterates | → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen39% | — | Initiates | → Outperform | Get Alert |
| 06/11/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | -15.54% | Evercore ISI Group | Liisa Bayko70% | $50 → $38 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 24.47% | Canaccord Genuity | Edward Nash66% | $59 → $56 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | -33.32% | B of A Securities | Alexandria Hammond43% | → $30 | Reinstates | → Neutral | Get Alert |
| 03/05/2024 | Buy Now | -6.65% | UBS | Eliana Merle46% | $39 → $42 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 11.14% | HC Wainwright & Co. | Ed Arce62% | $43 → $50 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | -4.42% | HC Wainwright & Co. | Ed Arce62% | $40 → $43 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | -11.09% | HC Wainwright & Co. | Ed Arce62% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 10/12/2023 | Buy Now | -13.31% | UBS | Eliana Merle46% | $83 → $39 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | -8.87% | JP Morgan | Eric Joseph47% | $62 → $41 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | -11.09% | HC Wainwright & Co. | Ed Arce62% | $64 → $40 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | -13.31% | Cantor Fitzgerald | Prakhar Agrawal38% | $69 → $39 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | -26.65% | Morgan Stanley | Michael Ulz57% | $70 → $33 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | 53.37% | Cantor Fitzgerald | Prakhar Agrawal38% | → $69 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | Buy Now | 53.37% | Cantor Fitzgerald | Prakhar Agrawal38% | → $69 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 33.36% | Evercore ISI Group | Liisa Bayko70% | $50 → $60 | Maintains | Outperform | Get Alert |
| 09/05/2023 | Buy Now | 37.81% | JP Morgan | Eric Joseph47% | $49 → $62 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | 84.49% | UBS | Eliana Merle46% | → $83 | Initiates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | 55.59% | Morgan Stanley | Michael Ulz57% | $65 → $70 | Maintains | Overweight | Get Alert |
| 06/07/2023 | Buy Now | 42.25% | HC Wainwright & Co. | Ed Arce62% | $62 → $64 | Maintains | Buy | Get Alert |
| 05/17/2023 | Buy Now | 31.14% | Canaccord Genuity | Edward Nash66% | $58 → $59 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | 37.81% | HC Wainwright & Co. | Ed Arce62% | $64 → $62 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 28.92% | Canaccord Genuity | Edward Nash66% | $50 → $58 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | 42.25% | HC Wainwright & Co. | Ed Arce62% | → $64 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 44.48% | Morgan Stanley | Michael Ulz57% | → $65 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/07/2022 | Buy Now | -11.09% | Morgan Stanley | Matthew Harrison60% | $30 → $40 | Maintains | Equal-Weight | Get Alert |
| 11/07/2022 | Buy Now | 42.25% | HC Wainwright & Co. | Ed Arce62% | $62 → $64 | Maintains | Buy | Get Alert |
| 09/14/2022 | Buy Now | -33.32% | Morgan Stanley | Matthew Harrison60% | $26 → $30 | Maintains | Equal-Weight | Get Alert |
| 09/14/2022 | Buy Now | 11.14% | Evercore ISI Group | Liisa Bayko70% | $10 → $50 | Upgrade | In-Line → Outperform | Get Alert |
FAQ
What is the target price for Akero Therapeutics (AKRO) stock?
The latest price target for Akero Therapeutics (NASDAQ:AKRO) was reported by HC Wainwright & Co. on March 3, 2025. The analyst firm set a price target for $75.00 expecting AKRO to rise to within 12 months (a possible 63.76% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
The latest analyst rating for Akero Therapeutics (NASDAQ:AKRO) was provided by HC Wainwright & Co., and Akero Therapeutics maintained their buy rating.
When was the last upgrade for Akero Therapeutics (AKRO)?
The last upgrade for Akero Therapeutics Inc happened on January 30, 2025 when B of A Securities raised their price target to $63. B of A Securities previously had a neutral for Akero Therapeutics Inc.
When was the last downgrade for Akero Therapeutics (AKRO)?
There is no last downgrade for Akero Therapeutics.
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a maintained with a price target of $72.00 to $75.00. The current price Akero Therapeutics (AKRO) is trading at is $45.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.